share_log

Vivos Therapeutics | 8-K: Current report

Vivos Therapeutics | 8-K: Current report

Vivos Therapeutics | 8-K：重大事件
美股sec公告 ·  06/14 16:21
Moomoo AI 已提取核心信息
On June 10, 2024, Vivos Therapeutics, Inc., a medical technology company specializing in treatments for sleep-related breathing disorders, entered into a securities purchase agreement with V-CO Investors LLC, an affiliate of New Seneca Partners Inc. The agreement involved a private placement offering where Vivos sold shares and warrants to V-CO, resulting in gross proceeds of $7.5 million for Vivos. The funds are intended for general corporate purposes and working capital. Concurrently, Vivos' subsidiary VSI Providers, PLLC, and Rebis Health Holdings, LLC entered into a strategic alliance agreement for joint marketing and distribution, targeting sleep apnea treatment solutions. Additionally, a management services agreement was signed between Vivos, Airway Integrated Management Company, LLC, and V-CO, where V-CO will provide management and advisory services related to the strategic alliance. The private placement and strategic agreements were announced in a press release on June 12, 2024, and aim to enhance Vivos' revenue streams and potential profit through collaborative efforts in marketing and distribution.
On June 10, 2024, Vivos Therapeutics, Inc., a medical technology company specializing in treatments for sleep-related breathing disorders, entered into a securities purchase agreement with V-CO Investors LLC, an affiliate of New Seneca Partners Inc. The agreement involved a private placement offering where Vivos sold shares and warrants to V-CO, resulting in gross proceeds of $7.5 million for Vivos. The funds are intended for general corporate purposes and working capital. Concurrently, Vivos' subsidiary VSI Providers, PLLC, and Rebis Health Holdings, LLC entered into a strategic alliance agreement for joint marketing and distribution, targeting sleep apnea treatment solutions. Additionally, a management services agreement was signed between Vivos, Airway Integrated Management Company, LLC, and V-CO, where V-CO will provide management and advisory services related to the strategic alliance. The private placement and strategic agreements were announced in a press release on June 12, 2024, and aim to enhance Vivos' revenue streams and potential profit through collaborative efforts in marketing and distribution.
2024年6月10日，专注于睡眠相关呼吸障碍治疗的医疗科技公司Vivos Therapeutics, Inc.与New Seneca Partners Inc的关联公司V-CO Investors LLC签订了一份证券购买协议。该协议涉及一项定向增发，Vivos向V-CO出售股票和认股证，总募集资金达750万美元。这些资金计划用于一般企业用途和营运资金。同时，Vivos子公司VSI Providers, PLLC和Rebis Health Holdings，LLC签署了战略联盟协议，共同市场营销，目标是针对睡眠呼吸暂停治疗解决方案。此外，Vivos，Airway Integrated Management Company, LLC和V-CO签署了管理服务协议，V-CO将提供与战略联盟相关的管理和咨询服务。这些定向增发和战略协议于2024年6月12日的新闻发布会上宣布，旨在通过市场营销和分销方面的合作努力提高Vivos的营业收入流和潜在利润。
2024年6月10日，专注于睡眠相关呼吸障碍治疗的医疗科技公司Vivos Therapeutics, Inc.与New Seneca Partners Inc的关联公司V-CO Investors LLC签订了一份证券购买协议。该协议涉及一项定向增发，Vivos向V-CO出售股票和认股证，总募集资金达750万美元。这些资金计划用于一般企业用途和营运资金。同时，Vivos子公司VSI Providers, PLLC和Rebis Health Holdings，LLC签署了战略联盟协议，共同市场营销，目标是针对睡眠呼吸暂停治疗解决方案。此外，Vivos，Airway Integrated Management Company, LLC和V-CO签署了管理服务协议，V-CO将提供与战略联盟相关的管理和咨询服务。这些定向增发和战略协议于2024年6月12日的新闻发布会上宣布，旨在通过市场营销和分销方面的合作努力提高Vivos的营业收入流和潜在利润。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息